Avacincaptad pegol sodium
As of the edition of 20 October 2026, Avacincaptad pegol sodium is a drug: marketed, first approved in 2023 (US); acts on C5; US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Unknown
- Brand name
- Izervay
- First approved
- 4 August 2023 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Astellas
US protection
US protection ends in 2027.
The last listed US drug-substance patent ends in 2027. The application that gives this date is held by Astellas.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Avacincaptad pegol sodium.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| C5 | Complement C5 | P01031 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Astellas | Originator | 2023 to now |